Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA)
Sponsor: Abbott Medical Devices
This NA trial investigates Arrhythmia and Atrial Fibrillation and is currently completed. Abbott Medical Devices leads this study, which shows 12 recorded versions since 2009 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
May 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — May 2021 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed NA
-
Feb 2019 — Sep 2019 [monthly]
Completed NA
-
Jun 2018 — Feb 2019 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- Biosense Webster, Inc.
- Mayo Clinic
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .